Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

46 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Inhibition of delta-protein kinase C by delcasertib as an adjunct to primary percutaneous coronary intervention for acute anterior ST-segment elevation myocardial infarction: results of the PROTECTION AMI Randomized Controlled Trial.
Lincoff AM, Roe M, Aylward P, Galla J, Rynkiewicz A, Guetta V, Zelizko M, Kleiman N, White H, McErlean E, Erlinge D, Laine M, Dos Santos Ferreira JM, Goodman S, Mehta S, Atar D, Suryapranata H, Jensen SE, Forster T, Fernandez-Ortiz A, Schoors D, Radke P, Belli G, Brennan D, Bell G, Krucoff M; PROTECTION AMI Investigators. Lincoff AM, et al. Among authors: zelizko m. Eur Heart J. 2014 Oct 1;35(37):2516-23. doi: 10.1093/eurheartj/ehu177. Epub 2014 May 5. Eur Heart J. 2014. PMID: 24796339 Clinical Trial.
Long-term outcomes of patients with acute myocardial infarction presenting to hospitals without catheterization laboratory and randomized to immediate thrombolysis or interhospital transport for primary percutaneous coronary intervention. Five years' follow-up of the PRAGUE-2 Trial.
Widimsky P, Bilkova D, Penicka M, Novak M, Lanikova M, Porizka V, Groch L, Zelizko M, Budesinsky T, Aschermann M; PRAGUE Study Group Investigators. Widimsky P, et al. Among authors: zelizko m. Eur Heart J. 2007 Mar;28(6):679-84. doi: 10.1093/eurheartj/ehl535. Epub 2007 Feb 13. Eur Heart J. 2007. PMID: 17298968 Clinical Trial.
Transportation to primary percutaneous coronary intervention, compared with on-site fibrinolysis, is a strong independent predictor of functional status after myocardial infarction: 5-year follow-up of the PRAGUE-2 trial.
Mocova Bilkova D, Motovska Z, Prochazka B, Groch L, Zelizko M, Aschermann M, Widimsky P; PRAGUE Study Group Investigators. Mocova Bilkova D, et al. Among authors: zelizko m. Eur Heart J Acute Cardiovasc Care. 2014 Jun;3(2):105-9. doi: 10.1177/2048872613516016. Epub 2013 Dec 4. Eur Heart J Acute Cardiovasc Care. 2014. PMID: 24337919 Clinical Trial.
Very low lipoprotein(a) and increased mortality risk after myocardial infarction.
Wohlfahrt P, Jenča D, Melenovský V, Franeková J, Jabor A, Šramko M, Staněk V, Želízko M, Poledne R, Piťha J, Adámková V, Kautzner J. Wohlfahrt P, et al. Among authors: zelizko m. Eur J Intern Med. 2021 Sep;91:33-39. doi: 10.1016/j.ejim.2021.04.012. Epub 2021 May 8. Eur J Intern Med. 2021. PMID: 33972150
Iron deficiency and all-cause mortality after myocardial infarction.
Jenča D, Melenovský V, Mrázková J, Šramko M, Kotrč M, Želízko M, Adámková V, Piťha J, Kautzner J, Wohlfahrt P. Jenča D, et al. Among authors: zelizko m. Eur J Intern Med. 2024 Aug;126:102-108. doi: 10.1016/j.ejim.2024.04.020. Epub 2024 May 1. Eur J Intern Med. 2024. PMID: 38697863 Free article.
46 results